Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 901–1,000 of 1,008
Maymani, H., Hess, K. R., Groisberg, R., Hong, D. S., Naing, A., Piha-Paul, S. A., Jankú, F., Fu, S., Tsimberidou, A. M., Pant, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.020 · Cited by 39
Translational –omics: Future potential and current challenges in precision medicine
Wafi, A., & Mirnezami, R. (2018) · Methods · doi:10.1016/j.ymeth.2018.05.009 · Cited by 37
Predictive potential and need for standardization of PD-L1 immunohistochemistry
Prince, S. S., & Bubendorf, L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2445-7 · Cited by 40
Robin, T. P., Raben, D., & Schefter, T. E. (2018) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.06.009 · Cited by 39
Zhai, Y., Ma, H., Hui, Z., Zhao, L., Li, D., Liang, J., Wang, X., Xu, L., Chen, B., Tang, Y., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.10.032 · Cited by 38
Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
Nishida, T., Iijima, H., & Adachi, S. (2019) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v10.i2.17 · Cited by 43
Mechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 40
Augustyn, A., Adams, D. L., He, J., Qiao, Y., Verma, V., Liao, Z. X., Tang, C., Heymach, J. V., Tsao, A. S., & Lin, S. H. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.016 · Cited by 38
Management of Immune Checkpoint Inhibitor Toxicities
Durrechou, Q., Domblides, C., Sionneau, B., Lefort, F., Quivy, A., Ravaud, A., Gross‐Goupil, M., & Daste, A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s218756 · Cited by 39
Guaitoli, G., Tiseo, M., Maïo, M. D., Friboulet, L., & Facchinetti, F. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-941 · Cited by 40
Sugai, Y., Kadoya, N., Tanaka, S., Tanabe, S., Umeda, M., Yamamoto, T., Takeda, K., Dobashi, S., Ohashi, H., Takeda, K., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01810-9 · Cited by 38
Value-based radiotherapy: A new chapter of the ESTRO-HERO project
Lievens, Y. N., Borràs, J. M., Grau, C., & Aggarwal, A. K. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.05.007 · Cited by 39
Shi, H., Li, K., Ni, Y., Liang, X., & Zhao, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707198 · Cited by 40
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Xiong, A., Wang, J., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757993 · Cited by 44
Shi, Y., Fang, J., Zhou, C., Liu, A., Wang, Y., Meng, Q., Ding, C., Ai, B., Gu, Y., Yao, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14274 · Cited by 42
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients
Leger, M. C., Routy, B., & Juneau, D. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.04.010 · Cited by 41
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 42
Joseph, E. L. M., Kirilovsky, A., Lecoester, B., Sissy, C. E., Boullerot, L., Rangan, L., Marguier, A., Tochet, F., Dosset, M., Boustani, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002256 · Cited by 47
Saha, A., Dickinson, P. D., Shrimali, R. K., Salem, A., & Agarwal, S. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.01.043 · Cited by 41
Lim, J. U., Lee, E., Lee, S., Cho, H. J., Ahn, D. H., Hwang, Y., Choi, J. Y., Yeo, C. D., Park, C. K., & Kim, S. J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-633 · Cited by 45
CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
Lau, A. P. Y., Binstock, S. S. K., & Thu, K. L. (2023) · Cancers · doi:10.3390/cancers15215229 · Cited by 43
Wen, Y., Ye, S., Li, Z., Zhang, X., Liu, C., Wu, Y., Zheng, R., Xu, C., Tian, J., Shu, L., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03624-y · Cited by 39
Xia, H., Zhang, H., Ruan, Z., Zhang, H., Sun, L., Chen, H., Zhou, Y., Zhang, L., Bian, D., Zhu, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01861-w · Cited by 44
Advancements in conventional cancer therapy combined with immunotherapy
Li, H., Han, S., Dong, C., & Liu, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000067 · Cited by 45
Immunotherapy in patients with early stage resectable nonsmall cell lung cancer
Ghysen, K., & Vansteenkiste, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000497 · Cited by 36
PD-1 Blockade in Early-Stage Lung Cancer
Rosner, S., Reuss, J. E., & Forde, P. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-025205 · Cited by 39
Wong, D. J., Lee, J. J. X., Choo, S. P., Thng, C. H., & Hennedige, T. P. (2019) · Immunotherapy · doi:10.2217/imt-2018-0126 · Cited by 36
Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review
Kotlowska, M. P., Rueda, A. G., Olmedo, M. E., Benito, A., Roldán, A. S., Fernández-Méndez, M. Á., Gorospe, L., Palacios, J., & Garrido, P. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.02.017 · Cited by 36
Rengan, R., Mick, R., Pryma, D. A., Lin, L. L., Christodouleas, J. P., Plastaras, J. P., Simone, C. B., Gupta, A., Evans, T. L., Stevenson, J. P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2095 · Cited by 36
Gennen, K., Käsmann, L., Taugner, J., Eze, C., Karin, M., Roengvoraphoj, O., Neumann, J. H. L., Tufman, A., Orth, M., Reu, S., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-019-1453-3 · Cited by 43
Perrotta, F., Nankivell, M. G., Adizie, J. B., Maqsood, U., Elshafi, M., Jafri, S., Lerner, A. D., Woolhouse, I., Munavvar, M., Evison, M., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.059 · Cited by 38
Guidelines for clinical evaluation of anti‐cancer drugs
Minami, H., Kiyota, N., Kimbara, S., Ando, Y., Shimokata, T., Ohtsu, A., Fuse, N., Kuboki, Y., Shimizu, T., Yamamoto, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14967 · Cited by 41
Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Petrelli, F., Morelli, A. M., Luciani, A., Ghidini, A., & Solinas, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00824-3 · Cited by 43
Lu, M., Xu, J., Ye, Y., Wang, Y., Luo, S., & Gong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723609 · Cited by 41
Mayahara, H., Uehara, K., Harada, A., Kitatani, K., Yabuuchi, T., Miyazaki, S., Ishihara, T., Kawaguchi, H., Kubota, H., Okada, H., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-021-01979-z · Cited by 37
Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems
Doumat, G., Daher, D., Zerdan, M. B., Nasra, N., Bahmad, H. F., Recine, M. A., & Poppiti, R. (2023) · Current Oncology · doi:10.3390/curroncol30010055 · Cited by 37
Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?
Agahozo, M. C., Hammerl, D., Debets, R., Kok, M., & van Deurzen, C. H. M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0030-x · Cited by 38
Non-small-cell lung cancer: how to manage BRAF-mutated disease
Guaitoli, G., Zullo, L., Tiseo, M., Dankner, M., Rose, A. A. N., & Facchinetti, F. (2023) · Drugs in Context · doi:10.7573/dic.2022-11-3 · Cited by 37
Asmara, O. D., Tenda, E. D., Singh, G., Pitoyo, C. W., Rumende, C. M., Rajabto, W., Ananda, N. R., Trisnawati, I., Budiyono, E., Thahadian, H. F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.010 · Cited by 35
Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes
Listyoko, A. S., Okazaki, R., Harada, T., Inui, G., & Yamasaki, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1305638 · Cited by 47
Han, C., Qiu, J., Bai, L., Liu, T., Chen, J., Wang, H., & Dang, J. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.217 · Cited by 38
Aggarwal, C., Martínez‐Martí, A., Majem, M., Barlési, F., Carcereny, E., Chu, Q., Monnet, I., Sánchez-Hernández, A., Dakhil, S. R., Camidge, D. R., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.18440 · Cited by 39
Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy
Banna, G. L., Camerini, A., Bronte, G., Anile, G., Addeo, A., Rundo, F., Zanghì, G., Lal, R., & Libra, M. (2018) · Anticancer Research · doi:10.21873/anticanres.12647 · Cited by 37
The Role of Radiation Oncology in Immuno-Oncology
Meng, X., Feng, R., Yang, L., Xing, L., & Yu, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s04 · Cited by 36
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 38
Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
Casey, D. L., Lin, T.-Y., & Cheung, N. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00537 · Cited by 44
Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia
Maggio, I., Manuzzi, L., Lamberti, G., Ricci, A. D., Tober, N., & Campana, D. (2020) · Cancers · doi:10.3390/cancers12040832 · Cited by 36
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 36
Wu, Z., Man, S., Sun, R., Li, Z., Wu, Y., & Zuo, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106613 · Cited by 39
Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers
Wang, L., Qu, J., Zhou, N., Hou, H., Jiang, M., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110626 · Cited by 38
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 38
Evrard, D., Hourseau, M., Couvelard, A., Paradis, V., Gauthier, H., Raymond, É., Halimi, C., Barry, B., & Faivre, S. J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1844403 · Cited by 41
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 41
Li, L., Lu, G., Liu, Y., Gong, L., Zheng, X. Y., Zheng, H., Gu, W., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658690 · Cited by 42
Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab
LeClair, J. N., Merl, M. Y., Cohenuram, M. K., & Luon, D. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.006 · Cited by 38
Malhotra, J. D., Ryan, B. M., Patel, M. M., Chan, N., Guo, Y., Aisner, J., Jabbour, S. K., & Pine, S. R. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1377 · Cited by 42
A banner year for immunotherapy and targeted therapy
Carlisle, J. W., & Ramalingam, S. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0138-4 · Cited by 35
Sun, Y.-M., Wang, Y., Sun, X.-X., Chen, J., Gong, Z.-P., & Meng, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.558454 · Cited by 36
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 45
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Jung, C. Y., & Antonia, S. J. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.0120 · Cited by 35
Self-citationImmune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
Melosky, B. L., Juergens, R. A., McLeod, D., Leighl, N. B., Brade, A. M., Card, P. B., & Chu, Q. S.-C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.027 · Cited by 35
Xian, Z., Ma, L., Zhu, M., Li, G., Gai, J., Chang, Q., Huang, Y., Ju, D., & Wan, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.160 · Cited by 35
Self-citationLü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 36
Combining Immunotherapy with Radiation Therapy in Non–Small Cell Lung Cancer
Fitzgerald, K., & Simone, C. B. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.002 · Cited by 37
Chu, C., Chiu, T.-H., Wang, C., Chang, W., Huang, A. C., Liu, C., Wang, C., Ko, H., Chung, F., Hsu, P., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13426 · Cited by 36
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)
Mildner, F., Sopper, S., Amann, A., Pircher, A., Pall, G., Koeck, S., Naismith, E., Wolf, D. G. F., & Gamerith, G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102948 · Cited by 37
Pentheroudakis, G. E. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.023 · Cited by 34
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Liu, W., Zhang, L., Xiu, Z., Guo, J., Wang, L., Zhou, Y., Jiao, Y., Sun, M., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255491 · Cited by 37
Or, M., Liu, B., Lam, J., Vinod, S. K., Xuan, W., Yeghiaian‐Alvandi, R., & Hau, E. K. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-85131-7 · Cited by 40
Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, J., Hamada, A., Fujino, T., & Mitsudomi, T. (2021) · Cancers · doi:10.3390/cancers13164035 · Cited by 38
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
Voskamp, M. J., Li, S., van Daalen, K. R., Crnko, S., ten Broeke, T., & Bovenschen, N. (2021) · Cancers · doi:10.3390/cancers13215387 · Cited by 39
Huang, Y., Zhao, J. J., Soon, Y. Y., Wong, A. S. C., Aminkeng, F., Ang, Y. L. E., Asokumaran, Y., Low, J. L., Lee, M., Choo, J. R. E., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14667 · Cited by 40
Self-citationAdvances in immunotherapy in cervical cancer
Grau-Béjar, J. F., Fariñas-Madrid, L., García-Durán, C., García-Illescas, D., & Oaknin, A. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003758 · Cited by 40
Radio-induced lymphopenia in the era of anti-cancer immunotherapy
de Kermenguy, F., Meziani, L., Mondini, M., Clémenson, C., Morel, D., Deutsch, É., & Robert, C. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.002 · Cited by 46
Bockel, S., Durand, B., & Deutsch, É. (2018) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2018.07.136 · Cited by 36
Novel Immunotherapies for T Cell Lymphoma and Leukemia
Ghione, P., Moskowitz, A. J., Paola, N. D., Horwitz, S. M., & Ruella, M. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0480-8 · Cited by 37
Qiu, B., Xiong, M., Luo, Y., Li, Q., Chen, N., Chen, L., Guo, S., Wang, B., Huang, X., Lin, M., et al. (2021) · Practical Radiation Oncology · doi:10.1016/j.prro.2021.06.004 · Cited by 33
Self-citationCombinations of radiotherapy with immunotherapy in cervical cancer
Yang, X., Ren, H., & Fu, J. (2022) · Journal of Cancer · doi:10.7150/jca.65074 · Cited by 34
Yamamoto, T., Kabus, S., Bal, M. F., Keall, P., Moran, A., Wright, C. L., Benedict, S., Holland, D., Mahaffey, N., Qi, L., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.11.026 · Cited by 33
Peng, J., Zhang, L., Wang, L., Feng, H., Yao, D., Meng, R., Liu, X., Li, X., Liu, N., Tan, B., et al. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02308-2 · Cited by 36
Gene regulatory networks reveal sex difference in lung adenocarcinoma
Saha, E., Guebila, M. B., Fanfani, V., Fischer, J., Shutta, K. H., Mandros, P., DeMeo, D. L., Quackenbush, J. F., & Lopes‐Ramos, C. M. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00634-y · Cited by 37
Yegya‐Raman, N., Zou, W., Nie, K., Malhotra, J. D., & Jabbour, S. K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.29 · Cited by 33
The current state of oligometastatic and oligoprogressive non-small cell lung cancer
Tumati, V., & Iyengar, P. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.19 · Cited by 34
Overview of Ongoing Clinical Trials Investigating Combined Radiotherapy and Immunotherapy
Cushman, T. R., Caetano, M. S., Welsh, J. W., & Verma, V. (2018) · Immunotherapy · doi:10.2217/imt-2018-0019 · Cited by 35
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects
Long, L., Zhao, C., Muqimova, O., Zhao, X., Yang, J. L., & Chen, H. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-018-00746-5 · Cited by 34
Shaverdian, N., Offin, M. D., Rimner, A., Shepherd, A. F., Wu, A. J.-C., Rudin, C. M., Hellmann, M. D., Chaft, J. E., & Gomez, D. R. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.11.015 · Cited by 36
Dodson, A. R., Parry, S., Lissenberg-Witte, B. I., Haragan, A., Allen, D. G., O’Grady, A., McClean, E., Hughes, J., Miller, K., & Thunnissen, E. (2019) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.153 · Cited by 33
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer
Sasaki, A., Nakamura, Y., Togashi, Y., Kuno, H., Hojo, H., Kageyama, S., Nakamura, N., Takashima, K., Kadota, T., Yoda, Y., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01058-4 · Cited by 36
Digital quantitative assessment of PD-L1 using digital spatial profiling
Gupta, S., Zugazagoitia, J., Martínez-Morilla, S., Fuhrman, K. A., & Rimm, D. L. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-0424-5 · Cited by 34
Martin, D., Balermpas, P., Gollrad, J., Weiß, C., Valentini, C., Stuschke, M., Schäfer, H. S., Henkenberens, C., Debus, J., Krug, D. A., et al. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.010 · Cited by 37
Saitô, S., Abe, T., Kobayashi, N., Aoshika, T., Ryuno, Y., Igari, M., Hirai, R., Kumazaki, Y., Miura, Y., Kaira, K., et al. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.05.006 · Cited by 33
Chicas-Sett, R., Zafra, J., Morales-Orue, I., Castilla-Martinez, J., Francés, M. Á. B., González-Rodríguez, E., Rodríguez‐Abreu, D., & Couñago, F. (2020) · Cancers · doi:10.3390/cancers12082178 · Cited by 34
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Sheikholeslami, S. A., Salari, S., & Bashash, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103160 · Cited by 35
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
von Itzstein, M. S., Gonugunta, A. S., Mayo, H., Minna, J. D., & Gerber, D. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000484 · Cited by 33
Immune Checkpoint Inhibitors in the Treatment of Cancer
Zam, W., & Ali, L. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210325095022 · Cited by 37
Wang, X., Wang, H., Jiang, H., Qiao, L., & Guo, C. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4153 · Cited by 35
Self-citationDurvalumab for the treatment of non-small cell lung cancer
Murakami, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1699407 · Cited by 36
Self-citationLiu, F., Qiu, B., Yu, X., Luo, Y., Luo, Q., Wu, Y., Chen, N., Zhou, R., Guo, J., Wu, Q., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.009 · Cited by 33
Qiu, Z., Lu, Z., Huang, J., Zhong, Y., Yan, N., Kong, R., & Cheng, H. B. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122392 · Cited by 34
Wen, C., Wang, L., Piffkó, A., Chen, D., Yu, X., Zawieracz, K., Bugno, J., Yang, K., Naccasha, E. Z., Ji, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181612 · Cited by 39
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.